Seasonal influenza virus vaccine intranasal - BioDiem

Drug Profile

Seasonal influenza virus vaccine intranasal - BioDiem

Alternative Names: LAIV; LAIV Seasonal intranasal; Live attenuated influenza vaccine - BioDiem; Nasovac-S; SCH-900795; Seasonal influenza virus vaccine (intranasal) - BioDiem; Trivalent seasonal influenza virus vaccine - Serum Institute of India/Biodiem

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute of Experimental Medicine of the Russian Academy of Medical Sciences
  • Developer BioDiem; Changchun BCHT Biotechnology; Institute of Experimental Medicine of the Russian Academy of Medical Sciences
  • Class Attenuated vaccines; Influenza virus vaccines-live; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Influenza virus infections

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 14 Sep 2017 Changchun BCHT Biotechnology completes a phase III trial in Influenza virus infections (In adolescents, In children, Prevention) in China (Intranasal) (NCT02964065)
  • 01 Nov 2016 Phase-III clinical trials in Influenza virus infections (In adolescents, In children, Prevention) in China (Intranasal) (NCT02964065)
  • 22 Jun 2015 No recent reports on development identified - Phase-II for Influenza virus infections (Prevention) in European Union (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top